NOV 08, 2017 12:00 PM PST

Testing for Prostate-Specific Antigen (PSA): To Screen or Not to Screen

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Senior Health Scientist, Laboratory Research & Evaluation Branch, Division of Laboratory Systems, Centers for Surveillance, Epidemiology, & Laboratory Services, Centers for Disease Control
    Biography
      Dr. Shahram Shahangian has been a senior health scientist at the CDC's Division of Laboratory Systems since 1993. During this time, Dr. Shahangian has conducted studies in various areas of clinical laboratory medicine including clinical laboratory performance and proficiency testing, appropriate laboratory test utilization, problems in the total laboratory testing process, national surveys of coagulation laboratory testing practices, critical review of clinical laboratory quality indicators, and publications of good laboratory practices in molecular genetic testing, biochemical genetic tests, and newborn screening. He is the first or sole author of 25 original articles published in various peer-reviewed clinical laboratory journals. Prior to joining the CDC, Dr. Shahangian worked as a technical director and senior scientist in several biotechnology firms (1989-1993), as a research faculty member at the University of Texas MD Anderson Center (1985-1989), and as a postdoctoral fellow in clinical chemistry at the University of Utah School of Medicine (1982-1984). Dr. Shahangian received his PhD in 1982 and MS in 1979, both in biochemistry, from the University of Illinois at Urbana-Champaign. He has been a diplomate of the American Board of Clinical Chemistry since 1994 and a fellow of the National Academy of Clinical Biochemistry since 1995.

    Abstract:

    Despite the fact that screening for many cancers is associated with net harm, healthcare consumers continue to be screened. PSA is the most commonly performed laboratory screening test for cancer in men, but is associated with harms including complications such as erectile dysfunction, urinary incontinence and bowel dysfunction that may result from prostatectomy or radiation therapy after being diagnosed. In addition, various psychosocial morbidities may result from positive or false-positive results, and a cascade of follow-up tests and treatments. Appropriate use of laboratory screening tests has been documented to improve health outcomes.

    This presentation will describe/list:

    •    Major epidemiological biases that positively impact perception of screening effectiveness including lead-time and length biases
    •    Current recommendations in the United States for PSA screening for prostate cancer
    •    Criteria adopted by the World Health Organization (WHO) for effectiveness of any health screening program and how well the PSA test meets each.

    These relate to:

    o    Societal burden of the disease
    o    Clinical performance of the screening test
    o    Acceptability and feasibility
    o    Cost-effectiveness
    o    Ability for disease intervention
    o    Informed consent
    o    Better population health outcome with screening


    The presentation will also note the consequences from screening and the dilemmas with laboratory-based screening tests such as PSA, while providing some recommendations for future use of these tests. The discussions are aimed at raising awareness about various issues surrounding prostate cancer screening using the PSA test to promote better use of laboratory screening services. 


    Show Resources
    You May Also Like
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    Loading Comments...